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Abstract 
Background:  Available  evidence  shows  that  tetracycline 
family  has  cellular  and  molecular  mechanisms  to  protect 
neurons  and  oligodendrocytes  by  modulating  matrix 
metalloproteinases. We tried to compare the effectiveness 
of  intramuscular  and  subcutaneous  interferon  beta-1a  
(INF-β1a)  in  combination  with  oral  doxycycline  among 
patient  with  relapsing  remitting  multiple  sclerosis  (RRMS) 
and secondary progressive multiple sclerosis (SPMS). 
Methods: A double-blind clinical trial study was conducted 
at Hamedan University of  Medical and Health Sciences in 
Iran. Sixty patients with definite diagnosis of RRMS or SPMS 
were  treated  with  doxycycline  and  44  µg  subcutaneous  
IFN-β1a three times a week or 30 µg intramuscular IFN-β1a 
once a week for six months. Neurologic examinations were 
performed monthly until the end of the treatment. Changes 
in  expanded  disability  status  scale  (EDSS)  scores,  brain 
magnetic  resonance  images  (MRIs),  and  frequency  of 
receiving  corticosteroid  pulse  were  evaluated  before  and 
after the treatment. 
Results: Women constituted 88.3% of the participants. The 
mean  age  of  the  patients  was  32  years.  The  mean  EDSS 
scores reduced from 4.5 to 3.0. Based on the frequency 
of receiving corticosteroid pulse, relapse rate decreased 
from 3.2 to 0.8. MRI showed that the number, volume, 
and activity of the lesions decreased among 13.3% of the 
participants,  increased  among  15%,  and  remained 
persistent among 71.7%. 
Conclusion:  Combination  of  doxycycline  and  IFN-β1a 
can decrease relapse rate and improve EDSS scores in 
patients  with  RRMS  and  SPMS.  However,  it  does  not 
affect  MRI  changes.Furthercontrolled  clinical  trials  on 
greater  number  of  patients  with  MS  are  needed  to 
evaluate the efficacy of combination therapy. 
Introduction 
Multiple  sclerosis  (MS)  is  an  inflammatory 
autoimmune  disease  of  central  nervous  system 
(CNS)  and  spinal  cord.  Plaques  of  white  matter, 
caused  by  demyelination  and  loss  of  axon  in  this 
area, are characteristics of MS.1 Exact pathogenesis of 
MS  is  not  well  understood.  However,  various 
theories including immune defect, genetic capacity, 
infectious  diseases,  mental  stress,  biochemical 
agents, diet, vitamin deficiency, and allergic reaction 
have been suggested.2 
There  are  5-10  cycles  of  hidden  action  in  the 
course of MS that can be uncovered with magnetic  
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presonance  imaging  (MRI).  In  addition,  the  disease 
manifests  with  clinical  signs.3  The  most  important 
factor  in  determination  of  disease  process  is  relapse 
rate. Relapse is defined as acute or subacute clinical 
disorders  that  usually  occur  days  to  weeks  after  a 
cycle of recovery. Nearly 15% of the patients do not 
experience relapse.4 Recurrent relapses in the first two 
years,  advanced  progress  from  beginning,  male 
gender, and cerebellar or motor disorders can predict 
a poorer clinical course of the disease. On the other 
hand, female gender, dominant sensorial symptoms, 
and optic neuritis may have better prognosis.5 Based 
on disease pattern and progression, MS is categorized 
as  relapsing-remitting  MS  (RPMS),  primary-
progressive  MS  (PPMS),  secondary-progressive  MS 
(SPMS),  and  progressive-relapsing  MS  (PRMS). 
Nowadays,  the  most  common  scales  to  assess 
disability  of  patients  with  MS  is  Kurtzke  expanded 
disability status scale (EDSS).4 
The  aim  of  treatment  in  patients  with  MS  is  to 
regulate  the  clinical  course  and  reduce  the 
complications of the disease. While acute attacks are 
usually treated with corticosteroid, interferon beta-1a 
(IFN-β1a) is reserved for the regulation of the clinical 
course. Probable mechanisms for MS treatment with 
IFN-β1ainclude the inhibition of adhesion, synthesis, 
and transfer of matrix metalloproteinases (MMPs) and 
antigen blocking.3 
There is accumulating evidence that MMPs play a 
key  role  in  the  pathogenesis  of  many 
neuroinflammatory  diseases.  MMPs  can  be 
subdivided  intocollagenase,  gelatinase  A  and  B, 
stromelysins-1,  and  inhibitors  like  plasminogen 
activator  inhibitor-1  (PAI-1).  The  activity  of  other 
MMPs  is  closely  regulated  by  tissue  inhibitors  of 
metalloproteinase.6 MMP-9 is a well-known gelatinase 
B which is the most known protease.7,8 The roles  of 
MMP-9  are  disruption  of  blood-brain  barrier  (BBB), 
prevention  of  T  cell  migration  into  the  CNS,  and 
myelin destruction.9,10 Increased MMP-9 serum levels 
and decreased tissue inhibitor of metalloproteinase-1 
(TIMP-1) serum levels provoke BBB rupture and T cell 
entrance  to  the  nervous  system  which  result  in  the 
formation of new lesions.6,11,12 
Nearly all previous studies have focused on T cell 
penetration to the nervous system. However, the role 
of B-cells in the nervous system cannot be overlooked. 
In  fact,  although  T  cells  appear  in  the  beginning  of 
inflammation,  there  will  be  no  demyelinationin  the 
absence of B-cells.13 Treatment with IFN-β1a decreases 
MMP mRNA. It thus reduces T cell penetration to the 
CNS and cures the disease.11,14 
Boz et al. showed that body can rebalance MMP-
9/TIMP-1after six months of treatment with IFN-β1a.9 
Milanese  et  al.  reported  20.5%  decline  in  disability 
progression  following  beta  interferon  therapy.15 
Multiple studies in many regions have reported that 
the  use  of  beta  interferon  in  MS  for  two  years 
significantly  reduced  MRI  changes,  clinical  relapses, 
and yearly attacks.16 A systematic review article on 21 
studies  from  1993  to  2001  reported  IFN-β1a  (Rebif, 
Avonex)  to  be  significantly  more  effective  than 
interferon  beta-1b  (IFN-β1b;  Betaferon)  in  reducing 
the disability course of MS.17 
In  recent  years,  neuroprotective  effects  of 
tetracycline have been clearly shown in animal models 
with acute or chronic neurodegeneration.18 This recent 
finding  presented  a  new  point  of  view  about  the 
cellular  and  molecular  mechanisms  through  which 
tetracycline  protects  neurons  and  oligodendrocytes. 
However, only the second generation of tetracyclines 
is  usable  since  they  contain  minocycline  and 
doxycycline  which  are  semisynthetic.  Among  the 
characteristics of these drugs are passing BBB easily 
and  inhibiting  MMP.19  Doxycycline  is  absorbed 
rapidly and completely from the gastrointestinal tract. 
Since  it  is  lipid  soluble,  it  highly  penetrates  to 
cerebrospinal  fluid  (CSF).  Doxycycline  is  tolerated 
much better than minocycline and is a strong MMP 
inhibitor.  Since  MMP-9  can  cleavage  and  deactivate 
IFN-b,  it  can  cause  relapse  during  treatment. 
Therefore,  relapse  reduction  can  be  expected 
following treatment with doxycycline.20 
Minagar et al. investigated combined therapy with 
IFN-β1a and doxycycline in 15 patients with RRMS. 
Individuals  with  RRMS  taking  IFN-β1a  with 
breakthrough  disease  activity  took  100  mg 
doxycycline daily for four months. During the study, 
only  one  patient  experienced  a  relapse  and  adverse 
effects  were  little.  There  were  no  unexpected  or 
synergistic  adverse  effects  associated  with 
combination therapy. The authors thus concluded that 
a  combination  of  intramuscular  IFN-β1a  and  oral 
doxycycline  treatment  is  effective,  safe,  and  well 
tolerated.20 
Until  now,  evidence  about  latest  treatments  to 
prevent  the  progressive  course  of  MS  has  been 
contrasting. Therefore, we designed a trial to evaluate 
the effectiveness of a combination of doxycycline and 
IFN-β1a in treatment of MS. 
Materials and Methods 
On  the  base  of  Poser  et  al.21  and  McDonald  et 
al.22diagnostic  criteria,  14-51  year-old  patients  with 
definite  diagnosis  of  MS  were  enrolled.  Patients  were 
included  if  they  had  RRMS  or  SPMS  and  had  not 
responded to therapy (at least two relapses or one point 
increase on the EDSS before during the past year). All 
subjects had EDSS scores of 0-5.5 and could walk.  
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Relapse  was  defined  as  appearance  or 
recrudescence  of  one  or  two  neurological  defects 
without fever which last for at least 24 hours with a 
30-day  interval  between  the  two  attacks.  SPMS  was 
defined  as  a  deteriorative  course  and  independent 
relapse  that  lasted  for  at  least  six  months  following 
one  course  of  RRMS.  Inclusion  criteria  for  SPMS 
patients was EDSS scores less than 5.5, more than two 
relapses  in  the  history  of  patients,  and  one  point 
increase  on the EDSS during the past two years.  
Patients  in  both  groups  were  excluded  in  case  of 
receiving corticosteroid therapy during the three months 
before the study, receiving immunosuppressive therapy 
with  cytotoxic  agents,  pregnancy,  breastfeeding,  or 
intolerance or sensitivity to doxycycline. 
Demographic  and  clinical  characteristics  of  the 
participants  were  recorded  in  a  questionnaire  after 
obtaining informed consents from all 60 patients (7 men 
and  53  women).  The  subjects  received  44  µg 
subcutaneous IFN-b1a (Rebif) three times a week or 30 
µgintramuscular IFN-b1a (Avonex or Cinnovex) once a 
week.  Both  methods  were  combined  with  100  mg 
doxycycline  once  daily  for  six  months.  Patient 
outcomes were evaluated with relapse rate on the basis 
of corticosteroid pulse and EDDS point changes.  
Changes  and  deterioration  in  clinical  disability 
after  of  six  months  of  treatment  were  assessed  by 
brain  MRI  before  and  after  therapy.  Standard  brain 
MRI was taken from each patient with a 1.5-T scanner 
(imaging protocol: T1 sagittal, T1 and T2 axial, fluid 
attenuated  inversion  recoveryimages).  A 
neuroradiologist who was blinded to patients' clinical 
data  counted  the  number  of  contrast-enhancing 
lesions on brain MRIs. 
Results 
Sixty patients with RRMS or SPMS who were taking 
IFN-β1a  and  had  experienced  breakthrough  disease 
activity were enrolled. The mean age of participants 
was 32.0 ± 1.8 years. Women constituted 88.3% of the 
population.  The  mean  disease  duration  was  
51.0 ± 41.2 months. The mean EDSS scores before and 
after  treatment  were  4.5  ±  0.9  and  3.0  ±  1.3, 
respectively. Based on corticosteroid pulse, the mean 
relapse rates before and after treatment were 3.2 ± 3.3 
and 0.8 ± 0.8, respectively (Tables 1 and 2). 
 
Table  1.  Frequency  of  corticosteroid  pulse  therapy  in 
patients  before  and  after  combination  therapy  with 
interferon beta-1a and doxycycline 
Steroid pulse  Before therapy  After therapy 
0-3  35 (58.3)  58 (96.7) 
4-5  15 (24.9)  2 (3.3) 
6-10  8 (13.3)  0 (0) 
11-19  2 (3.5)  0 (0) 
Values are expressed as n (%). 
Table 2. Expanded disability  status scale (EDSS) scores 
and steroid pulse in patients before and after combination 
therapy with interferon beta-1a and doxycycline 
Clinical evaluation  Before 
therapy 
After 
therapy 
P 
EDDS score  4.5 ± 0 .9  3.0 ± 1.3  < 0.001 
Steroid pulse  3.2 ± 3.3  0.8 ± 0.8  < 0.001 
Values are expressed as mean ± SD. 
 
The mean number, volume, and activity of contrast-
enhancing lesions on brain MRIs decreased in 13.3% 
of participants and increased in 15%. No changes were 
observed in 71.7% of the  study  subjects.  No serious 
adverse effects, laboratory disturbance, or unexpected 
adverse events were reported. 
Discussion 
There  is  growing  interest  in  combination  therapy  to 
stabilize the clinical course, reduce the rate of clinical 
relapses, and decelerate the progressive course of the 
underlying  pathologic  mechanisms  of  MS.23  This 
study evaluated the efficacy, tolerability and safety of 
combination  therapy  with  IFN-β1a  and  oral 
doxycycline,  a  potent  inhibitor  of  MMP,  in  patients 
with RRMS or SPMS. We found that a combination of 
intramuscular  IFN-β1a  and  oral  doxycycline  could 
reduce relapse rate and EDSS scores in MS patients. 
However, the combination could not reduce contrast-
enhancing lesions on brain MRI.  
An  open-label  study  assessed  11  patients  with 
RRMS  who  had  received  doxycycline  and 
intramuscular  IFN-β1a  for  at  least  six  months.  The 
authors  reported  that  lower  number  of  lesions  on 
brain MRI and reduced mean EDSS score (3.9 vs. 1.4) 
after  treatment.20  Another  research  surveyed  the 
effectiveness of a 4-month combination therapy with 
doxycycline  and  IFN-β1a  among  15  patients  with 
RRMS.  It  showed  decreased  number  of  lesions  and 
EDSS scores after treatment.20 Investigating the effects 
of  doxycycline  on  MMP-9suppression  in  brain 
arteriovenousmalformations showed that serum levels 
of  MMP-9  were  significantly  reducing  following 
doxycycline therapy.24 
Changes  in  the  appropriate  balance  of  MMP-
9/TIMP-1  are  pathological  effects  that  lead  to 
inflammation and demyelination. As MMP-9 increases 
and TIMP-1 decreases, BBB rupture occurs and T cells 
arrive into the nervous system and make damage. In 
course  of  active  MS,  IFN-b  therapy  increases  serum 
level  of  MMP-9.  However,  MMP-9  can  reduce  the 
effectiveness  of  interferon.  Since  doxycycline  is  a 
potent  inhibitor  of  MMP-9,  its  usage  is  expected  to 
decrease relapse rate. 
Conclusion 
Overall, data from this cohort study suggest that the Combination therapy with doxycycline and 
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combination  of  oral  doxycycline  and  IFN-β1a  may 
reduce relapse rate and EDSS scores in patients with 
MS.  Nevertheless,  it  was  not  found  to  reduce  the 
number  of  lesions  on  the  brain.  Further  controlled 
clinical trials with larger sample size are warranted to 
demonstrate the safety and efficacy of the mentioned 
combination over a longer period. 
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